Cancer is one of the most deadly monsters afflicting human health in this modern times. Cancer cases have significantly increased over the past few years. The survival rate has also increased, and it is expected that the trend will continue in the coming years. The increase is attributed to advances in cancer screening and detection methods and steady improvements in treatment processes. As medical researchers grapple with the crisis, most of them have been focusing on diagnosis and refining treatment procedures. In the cancer screening process, cancer institutions focus on patients without prior detected cancer. This effectively removes prior cancer victims from the early detection mechanism of other types of cancers.
Recent research shows that quite a significant number of people diagnosed with cancer are prior cancer victims. Using data from the Surveillance, Epidemiology, and End Results (SEER) program, researchers sought to determine the prior cancer prevalence rates amongst the population diagnosed with cancer. They concentrated on cases reported between January 2009 and December 2013. The research population was also divided into two groups, patients below 65 years and those above 65 years of age.
The outcome of the research indicated that up to 25 percent of adults above 65 years of age had had another cancer detected previously. And up to 11% of persons below 65 years of age had been diagnosed with cancer previously. In the overall population, 18.4% of those diagnosed had a prior cancer history.
Collecting patient data is a great idea, and it was the motivating factor for Eric Lefkofsky when he co-founded Tempus. With better infrastructure, Eric Lefkofsky believes that patient data can be better utilized to determine patient-specific treatment procedures. While there is an enormous amount of patient data, there is no known faster method of linking the data with therapeutic data. The traditional techniques take many days of research and results can rarely apply to current patients.
This is the gap that Eric Lefkofsky, through Tempus, hopes to bridge. The technological platform being developed at Tempus will connect researchers, clinicians, and patients in an effort to improve cancer care. Clinicians will be more capable of figuring out the treatments befitting a particular genomic description of specific patients.